Literature DB >> 32368178

A review of cancer immunotherapy: from the past, to the present, to the future.

K Esfahani1, L Roudaia1, N Buhlaiga1, S V Del Rincon2, N Papneja1, W H Miller1.   

Abstract

Compared with previous standards of care (including chemotherapy, radiotherapy, and surgery), cancer immunotherapy has brought significant improvements for patients in terms of survival and quality of life. Immunotherapy has now firmly established itself as a novel pillar of cancer care, from the metastatic stage to the adjuvant and neoadjuvant settings in numerous cancer types. In this review article, we highlight how the history of cancer immunotherapy paved the way for discoveries that are now part of the standard of care. We also highlight the current pitfalls and limitations of cancer checkpoint immunotherapy and how novel research in the fields of personalized cancer vaccines, autoimmunity, the microbiome, the tumour microenvironment, and metabolomics is aiming to solve those challenges. 2020 Multimed Inc.

Entities:  

Keywords:  Immune checkpoint inhibitors; immune-related adverse events; metabolomics; microbiome studies; personalized cancer vaccines

Mesh:

Year:  2020        PMID: 32368178      PMCID: PMC7194005          DOI: 10.3747/co.27.5223

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  108 in total

1.  Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.

Authors:  Beatriz M Carreno; Vincent Magrini; Michelle Becker-Hapak; Saghar Kaabinejadian; Jasreet Hundal; Allegra A Petti; Amy Ly; Wen-Rong Lie; William H Hildebrand; Elaine R Mardis; Gerald P Linette
Journal:  Science       Date:  2015-04-02       Impact factor: 47.728

2.  Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1.

Authors:  Mara Roxana Rubinstein; Jung Eun Baik; Stephen M Lagana; Richard P Han; William J Raab; Debashis Sahoo; Piero Dalerba; Timothy C Wang; Yiping W Han
Journal:  EMBO Rep       Date:  2019-03-04       Impact factor: 8.807

3.  Complete Tumor Response to Pembrolizumab and Allograft Preservation in Renal Allograft Recipient on Immunosuppressive Therapy.

Authors:  Masood Sadaat; Sekwon Jang
Journal:  J Oncol Pract       Date:  2017-12-19       Impact factor: 3.840

Review 4.  The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition.

Authors:  Priti S Hegde; Vaios Karanikas; Stefan Evers
Journal:  Clin Cancer Res       Date:  2016-04-15       Impact factor: 12.531

5.  Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.

Authors:  Javid J Moslehi; Joe-Elie Salem; Jeffrey A Sosman; Bénédicte Lebrun-Vignes; Douglas B Johnson
Journal:  Lancet       Date:  2018-03-10       Impact factor: 79.321

Review 6.  The role of AMPK in T cell metabolism and function.

Authors:  Eric H Ma; Maya C Poffenberger; Alison H-T Wong; Russell G Jones
Journal:  Curr Opin Immunol       Date:  2017-04-28       Impact factor: 7.486

7.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.

Authors:  Chih-Hao Chang; Jing Qiu; David O'Sullivan; Michael D Buck; Takuro Noguchi; Jonathan D Curtis; Qiongyu Chen; Mariel Gindin; Matthew M Gubin; Gerritje J W van der Windt; Elena Tonc; Robert D Schreiber; Edward J Pearce; Erika L Pearce
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

8.  Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

Authors:  Frank Stephen Hodi; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Charles Lance Cowey; Christopher D Lao; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier Francesco Ferrucci; Michael Smylie; Andrew Hill; David Hogg; Ivan Marquez-Rodas; Joel Jiang; Jasmine Rizzo; James Larkin; Jedd D Wolchok
Journal:  Lancet Oncol       Date:  2018-10-22       Impact factor: 41.316

9.  Gut microbiota from twins discordant for obesity modulate metabolism in mice.

Authors:  Vanessa K Ridaura; Jeremiah J Faith; Federico E Rey; Jiye Cheng; Alexis E Duncan; Andrew L Kau; Nicholas W Griffin; Vincent Lombard; Bernard Henrissat; James R Bain; Michael J Muehlbauer; Olga Ilkayeva; Clay F Semenkovich; Katsuhiko Funai; David K Hayashi; Barbara J Lyle; Margaret C Martini; Luke K Ursell; Jose C Clemente; William Van Treuren; William A Walters; Rob Knight; Christopher B Newgard; Andrew C Heath; Jeffrey I Gordon
Journal:  Science       Date:  2013-09-06       Impact factor: 47.728

10.  Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors.

Authors:  Adam Diehl; Mark Yarchoan; Alex Hopkins; Elizabeth Jaffee; Stuart A Grossman
Journal:  Oncotarget       Date:  2017-12-14
View more
  105 in total

1.  Dual agonist immunostimulatory nanoparticles combine with PD1 blockade for curative neoadjuvant immunotherapy of aggressive cancers.

Authors:  Prabhani U Atukorale; Taylor J Moon; Alexandr R Bokatch; Christina F Lusi; Jackson T Routhier; Victoria J Deng; Efstathios Karathanasis
Journal:  Nanoscale       Date:  2022-01-27       Impact factor: 7.790

Review 2.  Revisiting the HIF switch in the tumor and its immune microenvironment.

Authors:  Sophie J Cowman; Mei Yee Koh
Journal:  Trends Cancer       Date:  2021-11-04

Review 3.  Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update.

Authors:  Christo Kole; Nikolaos Charalampakis; Michail Vailas; Maria Tolia; Maria Sotiropoulou; Sergios Tsakatikas; Nikolaos-Iasonas Kouris; Marina Tsoli; Anna Koumarianou; Michalis V Karamouzis; Dimitrios Schizas
Journal:  Cancer Immunol Immunother       Date:  2021-09-01       Impact factor: 6.968

4.  SIRT1 and gynecological malignancies (Review).

Authors:  Jiayu Chen; Houzao Chen; Lingya Pan
Journal:  Oncol Rep       Date:  2021-03-02       Impact factor: 3.906

5.  Non-invasive Detection of Immunotherapy-Induced Adverse Events.

Authors:  Carolina A Ferreira; Pedram Heidari; Bahar Ataeinia; Nicoleta Sinevici; Meghan E Sise; Robert B Colvin; Eric Wehrenberg-Klee; Umar Mahmood
Journal:  Clin Cancer Res       Date:  2021-10-01       Impact factor: 12.531

6.  Ranking-Based Convolutional Neural Network Models for Peptide-MHC Class I Binding Prediction.

Authors:  Ziqi Chen; Martin Renqiang Min; Xia Ning
Journal:  Front Mol Biosci       Date:  2021-05-17

Review 7.  Recent Progress in Dendritic Cell-Based Cancer Immunotherapy.

Authors:  Kazuhiko Matsuo; Osamu Yoshie; Kosuke Kitahata; Momo Kamei; Yuta Hara; Takashi Nakayama
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

Review 8.  Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune response.

Authors:  Yarden Ariav; James H Ch'ng; Heather R Christofk; Noga Ron-Harel; Ayelet Erez
Journal:  Sci Adv       Date:  2021-05-19       Impact factor: 14.136

Review 9.  Vitamin D: Promises on the Horizon and Challenges Ahead for Fighting Pancreatic Cancer.

Authors:  Daoyan Wei; Liang Wang; Xiangsheng Zuo; Robert S Bresalier
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

Review 10.  Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines.

Authors:  Lantian Lu; Viet Tram Duong; Ahmed O Shalash; Mariusz Skwarczynski; Istvan Toth
Journal:  Vaccines (Basel)       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.